We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Artificial Intelligence the Next Big Thing in Biotech?
Read MoreHide Full Article
The healthcare industry is not immune to software and technological advancements. In fact, the use of emerging technologies like artificial intelligence (AI) has gradually begun to revolutionize research activities in the industry. Major advances in science and technology are also likely to improve diagnosis and treatment in the future.
AI and the Drug Industry
The pharma/biotech industry has started adopting artificial intelligence, the simulation of human intelligence processes by machines, especially computer systems, albeit slowly. It is touted as the next big emerging technology in the biotech industry as it can drastically reduce time and costs involved in developing life-saving drugs.
A significant amount of time is invested in identifying a potential disease target and testing whether a candidate can hit that target. With the use of AI, it is estimated that the drug design timeframe can be cut down from four to five years to one year, thereby resulting in drastic reduction in costs.
Drug/biotech companies can analyze huge amount of data by applying artificial intelligence and machine learning to identify patterns in ways that humans cannot. Artificial intelligence driven solutions can enable pharma/biotech companies to identify the appropriate patient population, reduce or eliminate the need for some studies, and in some cases even predict outcomes in a virtual patient.
Several collaborations have been formed in the past couple of years between big pharma/biotech players and small AI-driven companies, primarily startups to discover novel biological targets and molecules for pharma players using AI.
For example, last year, Glaxo (GSK - Free Report) collaborated with two external companies —Exscientia, a UK specialist in machine-learning and Insilico Medicine, a U.S. leader in AI-led drug discovery —to harness the power of AI. Glaxo also has a partnership with AI driven drug design and development company, Cloud Pharmaceuticals. The partnership aims to use AI for the discovery of novel small-molecule drugs. Sanofi (SNY - Free Report) also has a deal with Exscientia to find small molecule drugs for metabolic diseases such as diabetes.
Also, last year, Roche’s (RHHBY - Free Report) pharma arm, Genentech formed a research partnership with GNS Healthcare to power cancer drug development with the latter’s REFS causal machine learning and simulation AI platform. Amgen and Celgene have also invested in GNS Healthcare.
AstraZeneca (AZN - Free Report) collaborated with Boston-based BERG last year to use artificial intelligence for discovering novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease.
J&J (JNJ - Free Report) , Pfizer (PFE - Free Report) and Novartis (NVS - Free Report) have collaborations with IBM’s Watson Health. Per the deals, the companies can use Watson Health’s AI solutions and applications for drug discovery and to accelerate cancer research efforts.
Though the use of AI in biotech for drug discovery and other purposes is in relatively early stages, a broad-scale adoption is expected by 2025.
Conclusion
While the healthcare space is growing by leaps and bounds on the back of emerging technologies like AI, mounting concerns around privacy, data protection and governance prevail. Also, many of the AI research companies overestimate their achievements, something that drug/biotech companies should be wary of. Nonetheless, this nascent technology holds ample promise and its proper execution will definitely prove to be a trump card for the space.
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
Image: Bigstock
Is Artificial Intelligence the Next Big Thing in Biotech?
The healthcare industry is not immune to software and technological advancements. In fact, the use of emerging technologies like artificial intelligence (AI) has gradually begun to revolutionize research activities in the industry. Major advances in science and technology are also likely to improve diagnosis and treatment in the future.
AI and the Drug Industry
The pharma/biotech industry has started adopting artificial intelligence, the simulation of human intelligence processes by machines, especially computer systems, albeit slowly. It is touted as the next big emerging technology in the biotech industry as it can drastically reduce time and costs involved in developing life-saving drugs.
A significant amount of time is invested in identifying a potential disease target and testing whether a candidate can hit that target. With the use of AI, it is estimated that the drug design timeframe can be cut down from four to five years to one year, thereby resulting in drastic reduction in costs.
Drug/biotech companies can analyze huge amount of data by applying artificial intelligence and machine learning to identify patterns in ways that humans cannot. Artificial intelligence driven solutions can enable pharma/biotech companies to identify the appropriate patient population, reduce or eliminate the need for some studies, and in some cases even predict outcomes in a virtual patient.
Several collaborations have been formed in the past couple of years between big pharma/biotech players and small AI-driven companies, primarily startups to discover novel biological targets and molecules for pharma players using AI.
For example, last year, Glaxo (GSK - Free Report) collaborated with two external companies —Exscientia, a UK specialist in machine-learning and Insilico Medicine, a U.S. leader in AI-led drug discovery —to harness the power of AI. Glaxo also has a partnership with AI driven drug design and development company, Cloud Pharmaceuticals. The partnership aims to use AI for the discovery of novel small-molecule drugs. Sanofi (SNY - Free Report) also has a deal with Exscientia to find small molecule drugs for metabolic diseases such as diabetes.
Also, last year, Roche’s (RHHBY - Free Report) pharma arm, Genentech formed a research partnership with GNS Healthcare to power cancer drug development with the latter’s REFS causal machine learning and simulation AI platform. Amgen and Celgene have also invested in GNS Healthcare.
AstraZeneca (AZN - Free Report) collaborated with Boston-based BERG last year to use artificial intelligence for discovering novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease.
J&J (JNJ - Free Report) , Pfizer (PFE - Free Report) and Novartis (NVS - Free Report) have collaborations with IBM’s Watson Health. Per the deals, the companies can use Watson Health’s AI solutions and applications for drug discovery and to accelerate cancer research efforts.
Among all these big names, Bristol-Myers sports a Zacks Rank #1 (Strong Buy) while Lilly and Roche are #2 Ranked stocks. You can see the complete list of today’s Zacks #1 Rank stocks here.
Though the use of AI in biotech for drug discovery and other purposes is in relatively early stages, a broad-scale adoption is expected by 2025.
Conclusion
While the healthcare space is growing by leaps and bounds on the back of emerging technologies like AI, mounting concerns around privacy, data protection and governance prevail. Also, many of the AI research companies overestimate their achievements, something that drug/biotech companies should be wary of. Nonetheless, this nascent technology holds ample promise and its proper execution will definitely prove to be a trump card for the space.
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>